Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Anebulo Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anebulo Pharmaceuticals şirketinin toplam hissedar öz sermayesi $3.8M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $4.1M ve $260.6K dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$3.09m
Eşitlik	US$3.81m
Toplam yükümlülükler	US$260.58k
Toplam varlıklar	US$4.07m

Son finansal sağlık güncellemeleri

Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 22

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Feb 18

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Jul 03

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 07

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Nov 19

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 28

Recent updates

Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 22

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Feb 18

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Jul 03

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 07

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Nov 19

Anebulo Pharmaceuticals to launch private investment in public equity financing

Sep 26

Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03

Sep 09

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 28

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 15

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Nov 04

Anebulo Pharmaceuticals reports FQ3 results

Jun 21

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ANEB 'nin kısa vadeli varlıkları ( $3.5M ) kısa vadeli yükümlülüklerini ( $260.6K ) aşıyor.

Uzun Vadeli Yükümlülükler: ANEB un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ANEB borçsuzdur.

Borcun Azaltılması: ANEB un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ANEB şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: ANEB un, serbest nakit akışı her yıl % 27 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Anebulo Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Recent updates

Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Anebulo Pharmaceuticals, Inc., Annual General Meeting, Nov 20, 2023

New major risk - Share price stability

Anebulo Pharmaceuticals, Inc. Appoints Richie Cunningham as CEO

New major risk - Financial position

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Anebulo Pharmaceuticals, Inc. Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Price target decreased to US$8.00

High number of new and inexperienced directors

Anebulo Pharmaceuticals, Inc. Appoints Nat Calloway as Class II Director

Anebulo Pharmaceuticals, Inc., Annual General Meeting, Oct 28, 2022

Anebulo Pharmaceuticals, Inc. announced that it has received $6.646748 million in funding from 22NW, LP, Nantahala Capital Management, LLC, Brightleaf Capital, ADAR1 Capital Management, LLC, and other investors

Anebulo Pharmaceuticals, Inc. announced that it expects to receive $6.646748 million in funding from 22NW, LP and other investors

Anebulo Pharmaceuticals, Inc. Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals to launch private investment in public equity financing

Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03

Anebulo Pharmaceuticals Announces Positive Topline Data for Aneb-001 from A Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

High number of new and inexperienced directors

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Anebulo Pharmaceuticals, Inc.(NasdaqCM:ANEB) dropped from Russell Microcap Value Index

Anebulo Pharmaceuticals, Inc. Announces Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

Anebulo Pharmaceuticals, Inc. Appoints Kenneth Cundy as Chief Scientific Officer

Anebulo Pharmaceuticals, Inc. Appoints Kenneth Cundy as Chief Scientific Officer

Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of A Phase 2 Clinical Trial and Provides Guidance on IND Submission

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Anebulo Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Anebulo Pharmaceuticals, Inc Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial

Anebulo Pharmaceuticals reports FQ3 results

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin